The study was terminated for business reasons.

This study will evaluate the safety, pharmacokinetics, and anti-tumor activity of MK-8808 in combination with cyclophosphamide, vincristine, and prednisolone (CVP), and as a single agent, for participants with B-lymphocyte antigen cluster of differentiation 20 (CD20)-positive follicular lymphoma who have had no prior chemotherapy. The primary study hypothesis is that MK-8808 will be safe and well tolerated in combination with CVP and as a single agent.

The study was terminated early by the Sponsor due to business reasons. All participants were discontinued from MK-8808 + CVP, but could continue to receive maintenance therapy with MabThera™ (rituximab) per standard of care.

Inclusion criteria:

• Histological diagnosis of CD20-positive follicular lymphoma, Grade 1, 2, or 3a (World Health Organization [WHO] 2008 classification) based on an excisional or incisional lymph node biopsy or a bone marrow biopsy.
• Ann Arbor Stage III or IV disease.
• Eastern Cooperative Oncology Group (ECOG) performance status of ≤2.
• Life expectancy >3 months with no expected need of immediate intervention to treat life-threatening complications.
• Adequate organ function.
• Participants must agree to use an adequate method of contraception starting with the first dose of study drug through 12 months (for females) or 90 days (for males) after the last dose of study drug.

Exclusion criteria:

• Histological Grade 3b or with >50% diffuse architectural pattern.

• Circulating malignant cells >25,000/mm^3

• Presence or history of central nervous system (CNS) disease (either CNS lymphoma or lymphomatous meningitis).

• Prior treatment with chemotherapy, rituximab, any other anti-CD20 compound, or any other type of anti-cancer compounds.

• Radiotherapy within 2 months prior to Cycle 1 Day 1.

• Current participation or has participated in a study with an investigational compound within 30 days prior to Cycle 1 Day 1.

• Concomitant disease that requires continuous therapy with prednisone at doses >20 mg per day.

• Any medical contraindication for prednisolone as being dosed in the CVP regimen.

• Poorly controlled diabetes mellitus, as defined by institutional or local standards.

• Grade >2 peripheral neuropathy.

• Has one of the following:

  1. is human immunodeficiency virus (HIV)-positive
  2. is Hepatitis B surface antigen positive (HBsAg+) or is positive for antibodies to Hepatitis B core antigen (anti-HBcAg+)
  3. has antibodies to Hepatitis C virus

• Has one or more of the following:

  1. Active tuberculosis based on institutional diagnostic criteria and local practice guidelines.
  2. Evidence of a tuberculosis infection based on a chest X-ray (CXR) or computed tomography (CT) scan performed within 3 months of dosing.
  3. History of a tuberculosis infection.

• Major surgical procedure within 4 weeks prior to Cycle 1 Day 1.

• Regular use (including "recreational" use) of any illicit drugs or recent history (within the last year) of drug or alcohol abuse or dependence.

• Pregnant or breastfeeding.

http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Up to 30 days after last dose of CVP therapy (up to 28 weeks)

Adverse events were not collected for participants who were switched to MabThera.

The study was terminated for business reasons. Not all planned analyses were performed